Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared an announcement on LinkedIn:
”Primary immune thrombocytopenia (ITP) is a rare autoimmune blood disorder characterized by low platelet counts leading to an increased risk of bleeding, bruising and chronic fatigue. For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects.
Today, we announced positive top-line results from our investigational treatment in primary ITP.
This marks our second positive data readout for this investigational asset as yesterday we announced positive Phase III results in Sjögren’s disease – reinforcing our efforts to addressing areas of high unmet needs across B-cell driven diseases.
With over two decades of experience advancing care in ITP, this milestone underscores our commitment to continuing to innovate with the aim of finding new and meaningful ways to improve patient outcomes.
I would like to extend my gratitude to the patients, families, and teams who made this possible as we reimagine medicine together.”
Read more about Shreeram Aradhye’s announcement here.
Stay updated on the latest breakthroughs in drug development with Hemostasis Today.
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia
-
Apr 5, 2026, 17:41Gevorg Yaghjyan: Attending an AI Conference on AI in Clinical Medicine, Research and Education
-
Apr 5, 2026, 17:41Ifeanyichukwu Ifechidere: The Mastermind of Clotting – A Thrombin Story
-
Apr 5, 2026, 17:38Thomas Ichim: Making iPSC Cells from Menstrual Blood Stem Cells